Back

Canagliflozin in patients with type 2 Diabetes and CKD experiencing deterioration in eGFR to <20 ml/min/1.73m2 in the CREDENCE Trial

29 August 2025 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Renal and cardiovascular disease (1) Renal Failure and Cardiovascular Disease ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Safia Chatur

Brigham and Women's Hospital, Harvard Medical School, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Correlation between renal function level and ventricular remodeling, and mechanistic study of slc10a6-mediated ventricular remodeling after chronic kidney disease
Mr W. Zhang (Guangzhou, CN)
Abstract Slides
Presentation thumbnail
Complement Factor D is an independent prognostic marker in patients with chronic kidney disease in the UK-Biobank
Doctor M. Berger (Aachen, DE)
Abstract Slides Video
Presentation thumbnail
Understanding arteriovenous fistula physiology: preoperative and early postoperative effects on left ventricular myocardial work
Doctor A. Safak Arslanhan (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Impact of statin therapy on mortality in chronic kidney disease patients without atherosclerotic cardiovascular disease: insights from american and chinese cohorts (MIMIC-IV and CIN-II Databases)
Mr W. Zhang (Guangzhou, CN)
Abstract Slides
Presentation thumbnail
Unique amino acid profile and prognostic significance of the Fischer ratio in end-stage kidney disease patients with cardiovascular disease
Assistant Professor K. Moribayashi (Miyazaki, JP)
Abstract Slides Video

Access the full session

Session thumbnail
Renal and cardiovascular disease (1)

The Event

Event poster

ESC Congress 2025

29 August 2025 10:15 CET
You may be interested in
thumbnail
Congress Presentation
Finerenone in patients with heart failure and deterioration in eGFR to <25ml/min/1.73m2 in the FINEARTS-HF Trial
thumbnail
Congress Presentation
Prevention of new-onset heart failure and renoprotective effect with sodium-glucose cotransporter 2 inhibitors in patients with chronic kidney disease
thumbnail
Congress Presentation
Predictors of worsening kidney function and their relation to SGLT2 inhibitor dapagliflozin administration in type 2 diabetes mellitus patients with chronic heart failure

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources